DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0009534 A1 Cooper Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0009534 A1 Cooper Et Al US 2006OOO9534A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0009534 A1 Cooper et al. (43) Pub. Date: Jan. 12, 2006 (54) PREVENTING AND/OR TREATING Publication Classification CARDIOVASCULAR DISEASE AND/OR ASSOCATED HEART FAILURE (51) Int. Cl. A6IK 3III.3 (2006.01) (76) Inventors: Garth J.S. Cooper, Auckland (NZ); (52) U.S. Cl. .............................................................. 514/673 John R. Baker, Auckland (NZ) (57) ABSTRACT Correspondence Address: Methods are provided for reducing copper values for, by DUANE MORRIS LLP way of example, treating, preventing or ameliorating tissue 101 WEST BROADWAY damage Such as, for example, tissue damage that may be SUTE 900 caused by (i) disorders of the heart muscle (for example, SAN DIEGO, CA 92101-8285 (US) cardiomyopathy or myocarditis) Such as idiopathic cardi omyopathy, metabolic cardiomyopathy which includes dia Appl. No.: 11/221,298 betic cardiomyopathy, alcoholic cardiomyopathy, drug-in (21) duced cardiomyopathy, ischemic cardiomyopathy, and (22) Filed: Sep. 7, 2005 hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) Such as the Related U.S. Application Data aorta, the coronary arteries, the carotid arteries, the cere brovascular arteries, the renal arteries, the iliac arteries, the (63) Continuation of application No. 10/388,213, filed on femoral arteries, and the popliteal arteries, (iii) toxic, drug Mar. 12, 2003, now Pat. No. 6,951,890, and which is induced, and metabolic (including hypertensive and/or dia a continuation of application No. PCT/NZ03/00042, betic disorders of small blood vessels (microvascular dis filed on Mar. 10, 2003. ease) Such as the retinal arterioles, the glomerular arterioles, the Vasa nervorum, cardiac arterioles, and associated capil (60) Provisional application No. 60/364,382, filed on Mar. lary beds of the eye, the kidney, the heart, and the central and 12, 2002. peripheral nervous Systems, (iv) plaque rupture of athero matous lesions of major blood vessels Such as the aorta, the (30) Foreign Application Priority Data coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral Mar. 11, 2002 (NZ). 517725 arteries and the popliteal arteries, (v) diabetes or the com Mar. 8, 2002 (NZ)................................................ 517721 plications of diabetes. Patent Application Publication Jan. 12, 2006 Sheet 1 of 27 US 2006/0009534 A1 Normal Myocardium Reducing Substance & Free Copper S tem Cell Free Radicals Tissue Mediated D Repair amage Cardiomyopathy F G U R E 1 Patent Application Publication Jan. 12, 2006 Sheet 2 of 27 US 2006/0009534 A1 Hypothesis 1. Glyco-oxidation production (AGE" formation) Lipid or Protein + glucose - {Protein - AGE {Lipid - AGE Cu-AGE Protein or Cu-AGE Lipid -> Protein + 02 2. Superoxide dismutase 202 -- 2H' -) H202 -H 02 3. Haber-Weiss Reaction (Copper salt catalyst) H202 + 20, - 0 + OH- + OH *AGE = Advance Glycation Endproduct FIGURE 2 Patent Application Publication Jan. 12, 2006 Sheet 3 of 27 US 2006/0009534 A1 sn?e?sberpuessisessy :3uauue6w FGURE3 Patent Application Publication Jan. 12, 2006 Sheet 4 of 27 US 2006/0009534 A1 uue6uw:33 e?34snu,Iwa?epodelaousi elH FIGURE 4 Patent Application Publication Jan. 12, 2006 Sheet 5 of 27 US 2006/0009534 A1 200 -- STZ -be-Sham 150 -- STZ/D7 - -o-Sham D7 50 O O 1 2 3 4 5 6 7 8 9. 1 0 1 1 12 13 14 Time (weeks) FIGURES Patent Application Publication Jan. 12, 2006 Sheet 6 of 27 US 2006/0009534 A1 40 -- STZ -be - Sham 3 O Aa’YKA2-fiS --- slavorSTZ/D7 -2 O 10 y O O 1 2 3 4 5 6 7 8 9 10 1 1 12 13 14 Time (weeks) FIGURE 6 Patent Application Publication Jan. 12, 2006 Sheet 7 of 27 US 2006/0009534 A1 100 -- STZ -- Sham 75 -H STZ/D7 -o-Sham/D7 5 O 2 5 O 5 10 15 20 Preload (cmH2O) *p-0.05:STZ v STZ/D7 FIGURE 7 Patent Application Publication Jan. 12, 2006 Sheet 8 of 27 US 2006/0009534 A1 30 1S -- STZ S -%-Sham 5, 20 -- STZ/D7 -o-Sham/D7 s 10 9 O O O O 5 10 15 20 25 Preload (cmH2O) * p-0.05: STZ v STZ/D7, "p-0.05: STZ/D7 v Sham/D7. FIGURE 8 Patent Application Publication Jan. 12, 2006 Sheet 9 of 27 US 2006/0009534 A1 2 o E -- STZ e -- Sham S -- STZ/D7 N-1 S-s -o-Sham/D7 on 10 s C. C 9 O O O O 5 10 15 20 25 Preload (cmH2O) FIGURE 9 Patent Application Publication Jan. 12, 2006 Sheet 10 of 27 US 2006/0009534 A1 75 es -- STZ E -- Sham s 50 -- STZ/D7 s -- Sham/D7 O o 25 5 O O 5. 10 15 2O 25 Preload (cmH2O) * p-0.05:STZ v STZ/D7 FIGURE 10 Patent Application Publication Jan. 12, 2006 Sheet 11 of 27 US 2006/0009534 A1 -A-STZ -- Sham --STZ/D7 -o-Sham/D7 O 5 10 15 2O Preload (cmH2O) p<0.05: STZ v STZ/D7 FIGURE 11 Patent Application Publication Jan. 12, 2006 Sheet 12 of 27 US 2006/0009534 A1 -A-STZ -e-Sham -- STZ/D7 -o-Sham D7 O 5 10 15 20 Preload (cmH2O) p-0.05: STZ v STZ/D7, #p-0.05: STZ/D7 v Shan/D7. FIGURE 12 Patent Application Publication Jan. 12, 2006 Sheet 13 of 27 US 2006/0009534 A1 2 125 3 -o-Sham/D7 C 2 100 -e- Sham E -- STZ O5 75 -- STZ/D7 C 2 O-e 50 CD O St. 25 9 ? O ---- 60 80 100 120 Afterload (mmHg) Wilcoxon p<0.05 for STZ v STZ/D7 FIGURE 13 Patent Application Publication Jan. 12, 2006 Sheet 14 of 27 US 2006/0009534 A1 Flow-probe Afterload |Poona 95% O2 5% CO2 Pressure transducers FIGURE 14 Patent Application Publication Jan. 12, 2006 Sheet 15 of 27 US 2006/0009534 A1 FIGURE 1S Patent Application Publication Jan. 12, 2006 Sheet 16 of 27 US 2006/0009534 A1 -- nondiabetic: saline infused -a-diabetic: saline infused 1000 PF0.003 E. 750 PC0.0001 PC0.0001 P<0.000 E ? Y Y Y so 3. 500 GD . E 250 O m 30 90 time (min) 150 210 0.1 mg. kg 1.0 mg.kg 10 mg. kg' 100 mgkg' -- nondiabetic: drug infused -o- diabetic: drug infused 750 P-002 500 P<0.0001 PC00001 P=0.0003 E -- o ... 250 . - O 30 90 time (min) 150 210 0. mg kg." 1.0 mgkg' 10 mg.kg 100 mg.kg FIGURE 16 Patent Application Publication Jan. 12, 2006 Sheet 17 of 27 US 2006/0009534 A1 1000 -A-Saline infused -o- drug infused 750 r =0.044 P=0.0055 . 500 3t E 250 --saline infised -s-drug in?ised 500 P<0.0001 FIGURE 17 Patent Application Publication Jan. 12, 2006 Sheet 18 of 27 US 2006/0009534 A1 O.O4 -a-saline infused -g- drug infused P<0.0001 O.O3 PC0.0001 P<0.0001 Pa0.0001 -- 0.02 O 30 90 time (min) 150 210 0.1 mgkg' 1.0 mg.kg 10 mg.kg 100 mg.kg .04 -- Saline infused -- drug infused P<0.0001 0.03 P=0.005.5 P<0.0001 P<0.0001 0.02 0.01 O 3O 90 time (min) 150 210 f -1 - -1 f - 0.1 mg.kg 1.0 mg.kg 10 mg.kg 100 mg.kg FIGURE 18 Patent Application Publication Jan. 12, 2006 Sheet 19 of 27 US 2006/0009534 A1 -A - nondiabetic. Saline infused -a- diabetic. Saline infused O.OOOO12 - PeO.01.07 0.000009 P=0.0268 O.OOOOO6 OOOOOO3 O 30 90 time 150 210 t (min) t O. 1 mg.kg' 1.0 mg.kg' 1O mg.kg 100 mg.kg -H nondiabetic: drug infused -- diabetic: drug infused E 0.00012 P=0.0001 e 2, 000009 P=0.0001 =OOOO1 PEO.0002 c E O.OOOO6 PO.0318 9 s 5 0.00003 O O 30 90 time 150 0.1 mg.kg 1.0 mg.kg (min) 10 mg.kg 100 mg.kg FIGURE 19 Patent Application Publication Jan. 12, 2006 Sheet 20 of 27 US 2006/0009534 A1 nondiabetic: saline infused a nondiabetic: drug infused diabetic: Saline infused O diabetic: drug infused O.OO1 O.OOO75 0.0005 0.00025 FIGURE 20 Patent Application Publication Jan. 12, 2006 Sheet 21 of 27 US 2006/0009534 A1 a nondiabetic: drug infused O diabetic: drug infused a nondiabetic: saline infused a diabetic: saline infused P=0.003 0.0008 N 0.0001 0.0006 0.000075 0.0004 0.00005 0.0002 0.000025 FIGURE 21 Patent Application Publication Jan. 12, 2006 Sheet 22 of 27 US 2006/0009534 A1 0.01 -a-saline infused -- drug infused P=0.0035 0.0075 0.005 P=0. 00.15 P=0.0001 P-0.0293 0.0025 0.002 0.0015 0.001 5 0.0005 FIGURE 22 Patent Application Publication Jan. 12, 2006 Sheet 23 of 27 US 2006/0009534 A1 O.01 -a-saline infused -- drug infused P=0.0035 0.0075 O.005 P=0. 00.15 P=0.0001 P=0.0293 O.0025 0.002 -A-Saline infused -- drug infused 0.0015 O.001 0.0005 FIGURE 23 Patent Application Publication Jan. 12, 2006 Sheet 24 of 27 US 2006/0009534 A1 nondiabetic: saline infused a nondiabetic: drug infused diabetic: Saline infused O diabetic: drug infused 0.04 0.03 0.02 0.01 FIGURE 24 Patent Application Publication Jan. 12, 2006 Sheet 25 of 27 US 2006/0009534 A1 a nondiabetic: drug infused odiabetic: drug infused nondiabetic: saline infused a diabetic: Safine infused 0.00006 5 0.00015 s 0.0001.25 g a 0.00004 0.0001 G 5is O.OOOO75 s O.OOOO2 0.00005 C 0.000025 O FIGURE 25 Patent Application Publication Jan.
Load more

Recommended publications
  • Evaluation of Peripheral Microcirculation Improvement of Foot After Tarsal Tunnel Release in Diabetic Patients by Transcutaneous Oximetry
    EVALUATION OF PERIPHERAL MICROCIRCULATION IMPROVEMENT OF FOOT AFTER TARSAL TUNNEL RELEASE IN DIABETIC PATIENTS BY TRANSCUTANEOUS OXIMETRY EMILIO TRIGNANO, M.D., Ph.D.,1,2 NEFER FALLICO, M.D.,3* HUNG-CHI CHEN, M.D., M.H.A., F.A.C.S.,2 MARIO FAENZA, M.D.,1 ALFONSO BOLOGNINI, M.D.,1 ANDREA ARMENTI, M.D.,3 FABIO SANTANELLI DI POMPEO, M.D.,4 CORRADO RUBINO, M.D,5 and GIAN VITTORIO CAMPUS, M.D.1 Background: According to recent studies, peripheral nerve decompression in diabetic patients seems to not only improve nerve function, but also to increase microcirculation; thus decreasing the incidence of diabetic foot wounds and amputations. However, while the postop- erative improvement of nerve function is demonstrated, the changes in peripheral microcirculation have not been demonstrated yet. The aim of this study is to assess the degree of microcirculation improvement of foot after the tarsal tunnel release in the diabetic patients by using transcutaneous oximetry. Patients and methods: Twenty diabetic male patients aged between 43 and 72 years old (mean age 61.2 years old) suffering from diabetic peripheral neuropathy with superimposed nerve compression underwent transcutaneous oximetry (PtcO2) before and after tarsal tunnel release by placing an electrode on the skin at the level of the dorsum of the foot. Eight lower extremities presented diabetic foot wound preoperatively. Thirty-six lower extremities underwent surgical release of the tibialis posterior nerve only, whereas four lower extremities underwent the combined release of common peroneal nerve, anterior tibialis nerve, and poste- rior tibialis nerve. Results: Preoperative values of transcutaneous oximetry were below the critical threshold, that is, lower than 40 mmHg (29.1 6 5.4 mmHg).
    [Show full text]
  • Influence of Experimental Diabetes on the Microcirculation of Injured Peripheral Nerve Functional and Morphological Aspects
    Influence of Experimental Diabetes on the Microcirculation of Injured Peripheral Nerve Functional and Morphological Aspects James M. Kennedy and Douglas W. Zochodne Regeneration of diabetic axons has delays in onset, sumption of regenerating axons and cellular elements rate, and maturation. It is possible that microangiopa- during repair. For example, rises in blood flow, or hyper- thy of vasa nervorum, the vascular supply of the periph- emia, may be mediated by vasodilation of the extrinsic eral nerve, may render an unfavorable local vasa nervorum (2) by neuropeptides (notably calcitonin environment for nerve regeneration. We examined local gene-related peptide [CGRP], substance P, and vasoactive nerve blood flow proximal and distal to sciatic nerve intestinal peptide [VIP]) and mast cell-derived histamine. transection in rats with long-term (8 month) experi- Macrophage- and endothelial-derived nitric oxide (NO) mental streptozotocin diabetes using laser Doppler flowmetry and microelectrode hydrogen clearance po- also likely augments nerve blood flow at the injury site larography. We then correlated these findings, using in through vasodilation. At later stages of regeneration and vivo perfusion of an India ink preparation, by outlining repair, extensive neoangiogenesis may maintain a persis- the lumens of microvessels from unfixed nerve sections. tent hyperemic state (3). Revascularization from angiogen- There were no differences in baseline nerve blood flow esis into a peripheral nerve graft often precedes between diabetic and nondiabetic uninjured nerves, and regenerating axons (4), with fibers near blood vessels vessel number, density, and area were unaltered. After having the fastest regeneration rates (5). transection, there were greater rises in blood flow in Regenerative success in diabetes is impaired as a result proximal stumps of nondiabetic nerves than in diabetic of defects in the onset of regeneration (6), in elongation animals associated with a higher number, density, and caliber of epineurial vessels.
    [Show full text]
  • O'malley-MS-1969.Pdf
    DEVELOPMENT OF COLLATERAL CIRCULATION IN PARTIALLY EEVASCULARIZED FELINE SCIATIC NERVE 31 JOHN FRANCIS O'KALLEY A THESIS Submitted to the Faculty of the Graduate School of the Creighton University in Partial Fulfillment of the Requirements for the Degree of Master of Science in the Department of Anatomy Omaha, 1 969 V ACKNOWLEDGMENTS I am deeply indebted ana grateful to my advisor, Doctor Julian J. Baumel, for his patience, unselfish assistance, and constructive criticism throughout this investigation. I also wish to express my appreciation to Dr. R. Dale Smith for his valuaole assistance, to Dr. John 3arton for his help with the photogranhie representations, to Mrs. Edith Witt for the expert typing of the final manuscript, and to all the members of the faculty of the Anatomy Department for the excellent graduate training I have received. I especially wish to acknowledge my wife, Helen, for her understanding and perseverance through­ out my graduate studies, and it is to her that I dedicate this t h e s i s . vi TABLE OF CONTENTS A C KN OWLE DG ï T E N T S .......... LIST OF ILLUSTRATIONS Chapter I. INTRODUCTION ....................................... 1 II. HISTORY ............................................ 1+ Vasa Nervorum Collateral Circulation III. MATERIALS AND METHODS ............................ 10 Surgical Exposure Devascularization Vascular Injection Clearing IV. O B S E R V A T I O N S ....................................... l£ Sciatic Nerve - Anatomy Vascular Supply of Sciatic Nerve Art e r i e s Veins Development of Collateral Circulation Three-Day ‘/ascular Pattern Six-Seven Day Vascular Patterns Fourteen-Seventeen Day Vascular Patterns V. D I S C U S S I O N ......................................
    [Show full text]
  • Hyperglycemia, Lumbar Plexopathy and Hypokalemic Rhabdomyolysis Complicating Conn's Syndrome
    Hyperglycemia, Lumbar Plexopathy and Hypokalemic Rhabdomyolysis Complicating Conn's Syndrome Chi-Ping Chow, Christopher J. Symonds and Douglas W. Zochodne ABSTRACT: Background: Lumbosacral plexopathy is a complication of diabetes mellitus. Conn's syndrome from an aldosterone secreting adenoma may be associated with hypokalemia and rhabdomy­ olysis but mild hyperglycemia also usually occurs. Methods: Case description. Results: A 70-year-old male diagnosed as having Conn's syndrome, hypokalemia and mild hyperglycemia developed rhab­ domyolysis and lumbar plexopathy as a presenting feature of his hyperaldosteronism. His rhadbdomy- olysis rapidly cleared following correction of hypokalemia but recovery from the plexopathy occurred slowly over several months. Definite resection of the aldosterone secreting adenomas reversed the hyperglycemia. Conclusions: Our patient developed lumbar plexopathy resembling that associated with diabetes mellitus despite the presence of only mild and transient hyperglycemia. RESUME: Hyperglycemic, plexopathie lombaire et rhabdomyolyse hypokaliemique compliquant le syn­ drome de Conn. Introduction: La plexopathie lombosacree est une complication du diabete. Le syndrome de Conn du a un adenome secrefant de l'aldosterone peut etre associe a une hypokaliemie et a un rhabdomyolyse, mais une legere hyperglycemic peut aussi etre presente. Methode: Description d'un cas. Resultats: Un patient age de 70 ans porteur d'un syndrome de Conn, d'une hypokaliemie et d'une legere hyperglycemic a developpe une rhab­ domyolyse et une plexopathie lombaire comme manifestation initiale de son hyperaldosteronisme. La rhabdomyol­ yse s'est resolue rapidement suite a la correction de l'hypokaliemie, mais la guerison de sa plexopathie a pris plusieurs mois. La resection definitive de l'adenome secrefant de l'aldosterone a fait disparaitre l'hyperglycemie.
    [Show full text]
  • Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications
    Mangialardi, G., & Madeddu, P. (2016). Bone Marrow-Derived Stem Cells: A Mixed Blessing in the Multifaceted World of Diabetic Complications. Current diabetes reports, 16(5), [43]. https://doi.org/10.1007/s11892-016-0730-x Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1007/s11892-016-0730-x Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Current Medicine Group at http://dx.doi.org/ 10.1007/s11892-016-0730-x. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Curr Diab Rep (2016) 16: 43 DOI 10.1007/s11892-016-0730-x IMMUNOLOGY AND TRANSPLANTATION (L PIEMONTI AND V SORDI, SECTION EDITORS) Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications Giuseppe Mangialardi1 & Paolo Madeddu1 Published online: 30 March 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Diabetes is one of the main economic burdens in Introduction health care, which threatens to worsen dramatically if preva- lence forecasts are correct. What makes diabetes harmful is the Diabetes mellitus (DM) is a family of metabolic disorders multi-organ distribution of its microvascular and characterized by high blood glucose levels.
    [Show full text]
  • Bone Marrow Mononuclear Cells Have Neurovascular Tropism And
    Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy Hyongbum Kim, Emory University Jong-seon Park, Tufts University Yong Jin Choi, Emory University Mee-Ohk Kim, Emory University Yang Hoon Huh, Boston Biomedical Research Institute Sung-Whan Kim, Emory University Ji Woong Han, Emory University JiYoon Lee, Emory University Sinae Kim, Emory University Mackenzie A. Houge, Emory University Only first 10 authors above; see publication for full author list. Journal Title: STEM CELLS Volume: Volume 27, Number 7 Publisher: AlphaMed Press | 2009-07, Pages 1686-1696 Type of Work: Article | Post-print: After Peer Review Publisher DOI: 10.1002/stem.87 Permanent URL: http://pid.emory.edu/ark:/25593/fhm65 Final published version: http://onlinelibrary.wiley.com/doi/10.1002/stem.87/abstract Copyright information: © 2009 AlphaMed Press Accessed September 24, 2021 10:24 AM EDT NIH Public Access Author Manuscript Stem Cells. Author manuscript; available in PMC 2009 September 18. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Stem Cells. 2009 July ; 27(7): 1686±1696. doi:10.1002/stem.87. Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy Hyongbum Kima,b, Jong-seon Parkb, Yong Jin Choia,b, Mee-Ohk Kima,b, Yang Hoon Huhc, Sung-Whan Kima,b, Ji Woong Hana, JiYoon Leea,b, Sinae Kima, Mackenzie A. Hougea, Masaaki Iib, and Young-sup Yoona,b aDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA bDivision of Cardiovascular Medicine, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA cBoston Biomedical Research Institute, Watertown, Massachusetts, USA Abstract Bone marrow-derived mononuclear cells (BMNCs) have been shown to effectively treat ischemic cardiovascular diseases.
    [Show full text]
  • Nerve Blood Flow Control in Health & Disease:The Effects of Type 1
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 6-6-2014 12:00 AM Nerve Blood Flow Control in Health & Disease:The Effects of Type 1 Diabetes and Exercise Training Terry D. Olver The University of Western Ontario Supervisor Dr. J. Kevin Shoemaker The University of Western Ontario Graduate Program in Kinesiology A thesis submitted in partial fulfillment of the equirr ements for the degree in Doctor of Philosophy © Terry D. Olver 2014 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Cardiovascular Diseases Commons, Nervous System Diseases Commons, Nutritional and Metabolic Diseases Commons, and the Physiological Processes Commons Recommended Citation Olver, Terry D., "Nerve Blood Flow Control in Health & Disease:The Effects of Type 1 Diabetes and Exercise Training" (2014). Electronic Thesis and Dissertation Repository. 2109. https://ir.lib.uwo.ca/etd/2109 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Nerve Blood Flow Control in Health & Disease: The Effects of Type 1 Diabetes and Exercise Training (Thesis format: Integrated Article) by T. Dylan Olver Graduate Program in Kinesiology A thesis submitted in partial fulfillment of the requirements for the degree of Doctorate of Philosophy The School of Graduate and Postdoctoral Studies The University of Western Ontario London, Ontario, Canada ©T. Dylan Olver 2014 Abstract Peripheral nerve blood flow (NBF) is critical to nerve health. Impaired NBF control may contribute to the progression of diabetes peripheral neuropathy.
    [Show full text]
  • Local Events Within the Injured and Regenerating Peripheral Nerve Trunk: the Role of the Microenvironment an D Microcirculation
    Biomedical Reviews 1997; 8: 37-54 ©The Bulgarian-American Center, Varna, Bulgaria ISSN1310-392X LOCAL EVENTS WITHIN THE INJURED AND REGENERATING PERIPHERAL NERVE TRUNK: THE ROLE OF THE MICROENVIRONMENT AN D MICROCIRCULATION Douglas W. Zochodne Department of Clinical Neurosciences and The Neuroscience Research Group, University of Calgary, Calgary, Alberta, Canada SUMMARY down the distal nerve stump may be determined by the microenvironment it encounters on its road to recovery. • Peripheral nerves respond to injury in a unique Better understanding of these and other events in injured fashion. Changes in the local milieu of the injured nerve nerve trunks is needed to help solve the two cardinal trunk may determine both the likelihoods of regeneration problems of peripheral nerve injuries: functional disability and the production of neuropathic pain. For example, from impaired regeneration and the development of disabling changes in local blood flow within this microenvironment neuropathic pain. (Biomed Rev 1997; 8: 37-54) may reflect several interesting features of the repair process. Crushed and sectioned nerves develop hyperemia, or rises INTRODUCTION in local blood flow rather than ischemia, and these rises appear to be mediated by one of several mechanisms. • Peripheral nerve damage arising from trauma or dis Firstly, vasa nervorum, the blood vessels that supply nerve ease (acquired or inherited neuropathies) is common and dis trunks, are innervated by peptidergic fibers that may abling. Our understanding of local repair mechanisms of in participate in "neurogenic" inflammation, as occurs in jured peripheral nerves, however, is incomplete. The attempted other innervated tissues. Secondly, following a nerve section regeneration of fibers occurs within a nerve trunk microen or crush, early rises in blood flow may be mediated by local vironment milieu replete with inflammatory mediators, deposition of calcitonin gene-related peptide and nitric trophins, microvascular changes and proliferating cellular oxide from axonal endbulbs.
    [Show full text]
  • Pathophysiology of Diabetic Erectile Dysfunction: Potential Contribution of Vasa Nervorum and Advanced Glycation Endproducts
    International Journal of Impotence Research (2013) 25, 1–6 & 2013 Macmillan Publishers Limited All rights reserved 0955-9930/13 www.nature.com/ijir REVIEW Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts S Cellek1, NE Cameron2, MA Cotter2 and A Muneer3 Erectile dysfunction (ED) due to diabetes mellitus remains difficult to treat medically despite advances in pharmacotherapeutic approaches in the field. This unmet need has resulted in a recent re-focus on the pathophysiology, in order to understand the cellular and molecular mechanisms leading to ED in diabetes. Diabetes-induced ED is often resistant to PDE5 inhibitor treatment, thus there is a need to discover targets that may lead to novel approaches for a successful treatment. The aim of this brief review is to update the reader in some of the latest development on that front, with a particular focus on the role of impaired neuronal blood flow and the formation of advanced glycation endproducts. International Journal of Impotence Research (2013) 25, 1–6; doi:10.1038/ijir.2012.30; published online 23 August 2012 Keywords: advanced glycation endproducts; diabetes mellitus; erectile dysfunction; hypoxia; microvessel; nitric oxide; vasa nervorum INTRODUCTION disease and is likely to precede a coronary event by 5 years.8,9 Penile erection is the result of relaxation of smooth muscle in the Combined with the prevalence of obesity and metabolic syndrome cavernous body and associated blood vessels.1 Smooth muscle in these men, it is apparent that disease progression is likely to relaxation is mediated primarily by nitric oxide (NO), which is a reduce the efficacy of conventional pharmacotherapeutic options gaseous and labile mediator, yet one of the most potent for the treatment of ED in diabetic men.
    [Show full text]
  • Effectiveness of Frequency-Modulated Electromagnetic Neural Stimulation in the Treatment of Painful Diabetic Neuropathy
    Diabetologia (2005) 48: 817–823 DOI 10.1007/s00125-005-1734-2 ARTICLE E. Bosi . M. Conti . C. Vermigli . G. Cazzetta . E. Peretti . M. C. Cordoni . G. Galimberti . L. Scionti Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy Received: 7 December 2004 / Accepted: 23 February 2005 / Published online: 15 April 2005 # Springer-Verlag 2005 Abstract Aims/hypothesis: The largely unsatisfactory p< 0.05). No significant side effects were recorded during results reported for the pharmacological treatment of dia- the study. Conclusions/interpretation: FREMS is a safe betic neuropathy has spurred the search for alternative and effective therapy for neuropathic pain in patients with therapies. The aim of this study was to evaluate the efficacy diabetes and is able to modify some parameters of periph- of frequency-modulated electromagnetic neural stimula- eral nerve function. tion (FREMS) as a novel treatment for painful diabetic neuropathy. Methods: Patients (n=31) with painful neu- Keywords Clinical trial . Diabetes . Electromagnetic ropathy associated with decreased nerve conduction veloc- stimulation . Painful neuropathy ity (<40 m/s) and increased vibration perception threshold (>25 V) were enrolled in a randomised, double-blind, Abbreviations FREMS: frequency-modulated crossover study designed to compare the effects of FREMS electromagnetic neural stimulation . MNCV: motor nerve with those of placebo. Each patient received two series of conduction velocity . SF36: Short Form-36 questionnaire . ten treatments of either FREMS or placebo in random se- SNCV: sensory nerve conduction velocity . TENS: quence, with each series lasting no more than 3 weeks. The transcutaneous electrical nerve stimulation . VAS: visual primary efficacy end point was the change in pain mea- analogue scale .
    [Show full text]
  • Pericyte Loss and Detachment in Experimental Cisplatin-Induced Neuropathy
    Int. J. Morphol., 37(2):509-514, 2019. Pericyte Loss and Detachment in Experimental Cisplatin-Induced Neuropathy Pérdida y Desprendimiento de Pericitos en la Neuropatía Experimental Inducida por Cisplatino Depicha Jindatip; Worapat Nopparat; Phetnarin Kobutree; Atitaya Roumwong & Sithiporn Agthong JINDATIP, D.; NOPPARAT, W.; KOBUTREE, P.; ROUMWONG, A. & AGTHONG, S. Pericyte loss and detachment in experi- mental cisplatin-induced neuropathy. Int. J. Morphol., 37(2):509-514, 2019. SUMMARY: Cisplatin is an antineoplastic agent with neuropathy as one of its major side effect. However, effective treatment is lacking. Increasing evidence suggests that cisplatin might damage nerve capillaries leading to impaired functions of blood-nerve barrier (BNB) and neuropathy. This study was aimed to examine the effects of cisplatin on pericytes. Rats were either treated with intraperitoneal injection of cisplatin 2 mg/kg twice a week for five continuous weeks. Cisplatin-treated rats showed reduced body weight, thermal hypoalgesia and slow sciatic motor nerve conduction velocity, indicating neuropathy. The density of pericytes in the distal sciatic nerves determined by immunohistochemistry to desmin was significantly reduced in the cisplatin compared with that of the control groups. Electron microscopic analysis demonstrated the detachment of pericytes from endothelial cells including the disruption of shared basement membrane in the sciatic nerves from cisplatin-treated rats. These data indicate the pericyte loss and detachment caused by cisplatin. Future studies of the BNB components and functions after cisplatin treatment are needed and will be essential for the development of effective treatments against cisplatin-induced neuropathy. KEY WORDS: Pericyte; Cisplatin; Nerve; Neuropathy. INTRODUCTION Cisplatin has been used as anti-neoplastic agent (Peltonen et al., 2013), they might also be involved in the against cancers of various organs e.g.
    [Show full text]
  • Pentoxifylline Effects on Nerve Conduction Velocity and Blood Flow in Diabetic Rats
    CORE Metadata, citation and similar papers at core.ac.uk Provided by PubMed Central Int. Jnl. Experimental Diab. Res., Vol. 1, pp. 49-58 (C) 2000 OPA (Overseas Publishers Association) N.V. Reprints available directly from the publisher Published by license under Photocopying permitted by license only the Harwood Academic Publishers imprint, part of The Gordon and Breach Publishing Group. Printed in Malaysia. Pentoxifylline Effects on Nerve Conduction Velocity and Blood Flow in Diabetic Rats HEATHER FLINT, MARY A. COTTER and NORMAN E. CAMERON* Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland UK (Received 16 September 1999; Revised 27 October 1999; In final form 29 October 1999) Pentoxifylline has several actions that improve INTRODUCTION blood rheology and tissue perfusion and may there- fore potentially be applicable to diabetic neuropathy. The aims of this study were to ascertain whether 2 The early neuropathic changes in experimental weeks of treatment with pentoxifylline could correct diabetes, such as diminished conduction velo- nerve conduction velocity and blood flow deficits in city (NCV), are believed to be largely attribu- 6-week streptozotocin-diabetic rats and to examine whether the effects were blocked by co-treatment table to a reduction in nerve perfusion (Tuck with the cyclooxygenase inhibitor, flurbiprofen, or et al., 1984; Cameron et al., 1991). Parallels the nitric oxide synthase inhibitor, NG-nitro-L-argi may be drawn with reduced sural nerve blood nine. Diabetic deficits in sciatic motor and saphen- ous sensory nerve conduction velocity were 56.5% flow and the presence of endoneurial hypoxia and 69.8% corrected, respectively, with pentoxifyl- in neuropathic patients (Tesfaye et al., 1994).
    [Show full text]